Reuters logo
BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer
January 18, 2017 / 1:12 PM / 8 months ago

BRIEF-Daiichi Sankyo initiates phase 1/2 study of novel antibody drug conjugate in patients unresectable breast cancer

Jan 18 (Reuters) - Daiichi Sankyo Co Ltd

* Daiichi sankyo initiates phase 1/2 study of novel antibody drug conjugate u3-1402 in patients with her3-positive metastatic or unresectable breast cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below